GlobalData analysts have assessed the actions Madrigal Pharmaceuticals is taking to drive growth of its metabolic dysfunction-associated steatohepatitis (MASH) drug Rezdiffra, highlighting upcoming industry events as opportunities to boost awareness and adoption.
Following the announcement of Madrigal Pharmaceuticals’ second-quarter (Q2) 2024 financial results, Sravani Meka MPH, Senior Pharma Analyst at GlobalData, offers her view, “GlobalData estimates the diagnosed prevalent cases of NASH among individuals aged 18 and older in the US market to grow from 4.9 million in 2024 to 5.2 million in 2032. In March 2024, after years of research and anticipation, the FDA granted approval for Madrigal’s Rezdiffra (resmetirom), a pioneering treatment for adults with F2-F3 metabolic dysfunction-associated steatohepatitis (MASH). This significant achievement paved the way for Madrigal to release the second-quarter financial statement, Rezdiffra’s first full quarter of net sales in the US on 07 August 2024. With Rezdiffra now positioned as the first-line treatment for MASH in the US, Madrigal is set to lead in a market projected to see significant growth in the coming years.”
In its first full quarter on the market, Madrigal Pharmaceuticals’ Rezdiffra, the first treatment for metabolic dysfunction-associated steatohepatitis (MASH), achieved sales of $14.6 million. The company also reported that by the end of the second quarter, there were 2,000 patients on Rezdiffra, in a promising launch for the liver disease drug.
CONSHOHOCKEN, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic...
CONSHOHOCKEN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2024 financial results on Wednesday, August...
Late-breaking AI-based analysis of MAESTRO-NASH biopsy data demonstrates Rezdiffra improved key fibrotic features that are predictive of progression to decompensated cirrhosisNoninvasive test data...
Lilly pads tirzepatide`s MASH win with detailed fibrosis data
CONSHOHOCKEN, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the Goldman Sachs 45th Annual Global...
Viking`s MASH drug scores where Madrigal`s didn`t
CONSHOHOCKEN, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic...